TB Outcomes With ATV/r and Two Rifamycin-Containing TB Regimens in HIV/TB in India
Tuberculosis (TB) is the leading cause of death globally in HIV-infected individuals, and drug interactions can complicate treatment in this population. For those requiring antiretroviral therapy (ART) that includes a boosted protease inhibitor (PI), rifabutin is the recommended rifamycin, although the optimal dose is still in question. Our hypothesis was that HIV/TB co-infected patients treated…